Clinical trial results:
Investigation of a novel intervention in Acute HIV infection (AHI) on long term latent HIV reservoir size: A pilot study of antiretroviral therapy plus immunoglobulin in AHI

Summary

EudraCT number	2011-001982-42
Trial protocol	GB
Global end of trial date	30 March 2015

Results information

Result version number	v1 (current)
This version publication date	06 December 2018
First version publication date	06 December 2018
Summary attachment (see zip file)	FINAL STUDY REPORT (ivIG AHI GSTT report 20032017.pdf)

Trial information

Trial identification

Sponsor protocol code	J004

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Guy's and St Thomas' NHS Foundation Trust
Sponsor organisation address	Great Maze Pond, London, United Kingdom, SE19RT
Public contact	Julie Fox, Guy's & St. Thomas' NHS Foundation Trust, +44 207188 2643, julie.fox@gstt.nhs.uk
Scientific contact	Julie Fox, Guy's & St. Thomas' NHS Foundation Trust, +44 207188 2643, julie.fox@gstt.nhs.uk

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	30 March 2015
Is this the analysis of the primary completion data?	Yes
Primary completion date	30 March 2015
Global end of trial reached?	Yes
Global end of trial date	30 March 2015
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To investigate whether reactivation of HIV using immunoglobulin in individuals with AHI and virologically suppressed with ART, will reduce HIV viral reservoir at week 48.

Protection of trial subjects:

Safety blood tests (FBC, Urea and electrolytes and liver function tests) and adherence review are incorporated into the visit schedule. Any abnormalities or concerns will be addressed immediately and reported.

Background therapy:

NONE

Evidence for comparator:

INCLUSION CRITERIA
Males and females aged between 18-65 years (inclusive).
HIV antibody negative with p24/PCR DNA positive
OR
HIV antibody positive with a previous HIV negative test in the preceding 3 months
OR
Health Protection Agency HIV incident virus assay (estimating virus acquired within 3 months)
Ability and willingness to provide informed consent

Actual start date of recruitment	05 July 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 10
Worldwide total number of subjects	10
EEA total number of subjects	10

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	10
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Participants were recruited from one clinical site in London between 2013 to 2015

Pre-assignment

Screening details:

Males and females aged between 18-65 years (inclusive).
2) HIV antibody negative with p24/PCR DNA positive
OR
HIV antibody positive with a previous HIV negative test in the preceding 3 months
OR
Health Protection Agency HIV incident virus assay (estimating virus acquired within 3 months)
3) Ability and willingness to provide informed consent

Period 1

Period 1 title	Overall Trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Blinding implementation details:

At week 20 post commencemnet on ART therapy, participants are randomized to receive 5 days treatment with IVIG or no IVIG.

Arms

Are arms mutually exclusive?	Yes
Arm title	ARM B - IVIG Intervention

Arm description:

Participants randomised at week 20 post commencement on ART to receive 30g IVIG per day for five days

Arm type	Experimental
Investigational medicinal product name	IVIG
Investigational medicinal product code	OCTAGAM
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

30mg per day for 5 days

Arm title	ARM A - NO IVIG INTERVENTION

Arm description:

Randomised at 20 weeks post commencement on ante retro viral therapy to NOT receive IVIG

Arm type	CONTROL

No investigational medicinal product assigned in this arm

Number of subjects in period 1	ARM B - IVIG Intervention	ARM A - NO IVIG INTERVENTION
Started	5	5
Completed	5	5

Baseline characteristics

Reporting groups	
Reporting group title	Overall Trial

Reporting group description: -

Reporting group values	Overall Trial	Total	
Number of subjects	10	10	
Age categorical Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	10	10	
From 65-84 years	0	0	
85 years and over	0	0	
Gender categorical Units: Subjects			
Female	0	0	
Male	10	10	

End points

End points reporting groups

Reporting group title	ARM B - IVIG Intervention
Reporting group description:	
Participants randomised at week 20 post commencement on ART to receive 30g IVIG per day for five days	
Reporting group title	ARM A - NO IVIG INTERVENTION
Reporting group description:	
Randomised at 20 weeks post commencement on ante retro viral therapy to NOT receive IVIG	

Primary: Primary Endpoint

End point title	Primary Endpoint[1]
End point description:	
HIV viral reservoir - change in HIV proviral DNA quantification between enrolment and week 48	
End point type	Primary
End point timeframe:	
48 weeks post commencment on ART	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: See attached report for results

End point values	ARM B - IVIG Intervention	ARM A - NO IVIG INTERVENTION		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	5	5		
Units: whole	5	5		

Attachments (see zip file)	AHI RESULTS/ivIG AHI GSTT report 20032017.pdf

Statistical analyses

No statistical analyses for this end point

Secondary: Secondary Endpoint

End point title	Secondary Endpoint
End point description:	
Secondary outcome measures: measured as a comparison across arms between enrolment and week 48. a. Changes in CD8 T-cell activation: the percentage of CD3+ CD8+ cells expressing CD38+ b. Gut permeability: 16S DNA c. Host gene expression profiling d. Clinical outcome: CD4 T-cell counts, CD4 T cell decline, HIV RNA e. Immunological markers of T cell exhaustion: HLA-DR and PD-1 f. Inflammation (D-dimer)	
End point type	Secondary

End point timeframe:

Until 48 weeks post commencment on ART

End point values	ARM B - IVIG Intervention	ARM A - NO IVIG INTERVENTION		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	5	5		
Units: whole	5	5		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information	
Timeframe for reporting adverse events:	
Duration of the study	
Assessment type	Systematic

Dictionary used	
Dictionary name	MedDRA
Dictionary version	17.1

Reporting groups	
Reporting group title	ARM A - NO IVIG INTERVENTION
Reporting group description: -	
Reporting group title	ARM B - IVIG INTERVENTION
Reporting group description: -	

Serious adverse events	ARM A - NO IVIG INTERVENTION	ARM B - IVIG INTERVENTION	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 5 (0.00%)	0 / 5 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	ARM A - NO IVIG INTERVENTION	ARM B - IVIG INTERVENTION	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 5 (0.00%)	2 / 5 (40.00%)	
Respiratory, thoracic and mediastinal disorders			
Cold			
subjects affected / exposed	0 / 5 (0.00%)	1 / 5 (20.00%)	
occurrences (all)	0	1	
Infections and infestations			
Conjunctivitis			
subjects affected / exposed	0 / 5 (0.00%)	1 / 5 (20.00%)	
occurrences (all)	0	1	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
15 May 2014	Change in CI (to Julie Fox) * Update label to reflect change back to JF as CI * Multi-centre to single centre * Remove Imperial site *Clarification added to Hep B exclusion criteria

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported